Point-of-care Testing for Illicit Drugs and Alcohol Intoxication in an Emergency

描述（由申请人提供）：这一小企业创新研究第一阶段的建议侧重于开发一种小型，便携式，接触点分析仪器;用于同时检测酒精和麻醉品的筛选工具。核心技术是微型气相色谱仪（Mini-GC），它使用多检测器系统来分析药物痕迹。 在急诊室寻求治疗的病人中，有很大一部分是受滥用药物不良影响的人。Seacoast设想的低成本药物筛选器将为医生提供对患者的初步评估， 治疗决策和提高患者吞吐量。最重要的是，筛查测试是非侵入性的，不需要血液或尿液样本，而是从患者的皮肤上收集微量的麻醉剂和透皮酒精。这种样本拭子将是目前在机场用于寻找爆炸物痕迹的增强版。 海岸小说迷你 GC不依赖于庞大的载气罐，但通过协同传感器组的组合具有所需的灵敏度。具体来说，聚合物涂层石英晶体微量天平，金属氧化物半导体，和电化学乙醇传感器从气相色谱仪的检测器模块。 通过踝环监测透皮酒精和通过离子迁移谱检测毒品的想法已经分别应用多年;然而，这两个概念以前从未在一个仪器中结合，并以低成本提供。Seacoast的下一代Mini-GC多检测器系统将缩小这一差距。 该第二阶段计划由UCSD的医疗中心ER团队支持，该团队将组织一次急诊科现场试验，将Seacoast的诊断Mini-GC与最先进的尿液或血液毒理学实验室测试进行比较。

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I proposal focuses on the development of a small-sized, portable, point-of-contact analytical instrument; a screening tool for the simultaneous detection of alcohol and narcotics. The core technology is a miniature gas chromatograph (Mini-GC) that uses a multi-detector system to analyze the drug traces. Persons adversely affected by drugs of abuse comprise a substantial proportion of the patients that seek care in emergency departments. Seacoast's envisioned low-cost drug screener will provide physicians with an initial assessment of patients to facilitate the treatment decision making and enhance patient throughput. Most importantly, the screening test is non-invasive, does not require a blood or urine sample, but instead collects traces of narcotics and transdermal alcohol from a patient's skin. The sample swabs will be an enhanced version of what is currently used at airports to look for explosives traces. Seacoast's novel Mini GC is independent of bulky carrier gas tanks but has the needed sensitivity through a combination of a synergistic sensor set. Specifically, a polymer coated quartz crystal microbalance, a metal oxide semiconductor, and an electrochemical ethanol sensor from the gas chromatograph's detector module. The idea of monitoring transdermal alcohol by means of an ankle bracelet and the trace detection of narcotics by ion mobility spectroscopy have both been applied separately for years; however, the two concepts have never before been combined in one instrument and made available at low cost. Seacoast's next generation Mini-GC with the multi-detector system will close this gap. This Phase II program is supported by UCSD's Medical Center ER team, which will organize an emergency department field trial where Seacoast's diagnostic Mini-GC will be compared to state-of- the-art urine or blood based toxicological laboratory tests.